Jeremy Agresti

Jeremy Agresti has a strong background in research and development, particularly in the areas of next-generation sequencing (NGS) and biotechnology. Jeremy is currently the Founder and CTO of Triplebar, a position they have held since January 2019. Prior to this, they worked at Bio-Rad Laboratories, starting as a Senior Staff Scientist in January 2013. Jeremy then took on roles of increasing responsibility, including Advanced R&D Lead and R&D Manager 2, R&D Director, and finally Vice President of R&D, before leaving in January 2019.

Before their time at Bio-Rad, Agresti worked at Amyris Inc as a Scientist from October 2009 to January 2013. Here, they led an Advanced Research group and developed innovative technology for high-throughput screening of hydrocarbon-producing microbes.

Agresti's career started at Harvard University, where they worked as a Postdoctoral Fellow from February 2005 to October 2009. During this time, they focused on droplet microfluidics for biotechnology, inventing and demonstrating several core technologies in this field. Their work led to the creation of more than 10 patents and applications, forming the foundation for three separate companies' intellectual property.

Throughout their career, Agresti has shown a consistent ability to drive technical development, lead collaborations, and bring products from concept to market. Jeremy has also successfully managed teams and contributed to the invention and development of various technologies in the fields of NGS and biotechnology.

Jeremy Agresti completed their education in a chronological order, starting with a Bachelor of Science (BS) degree in Genetics from the University of California, Davis, which they obtained from 1993 to 1996. Jeremy then pursued a Master of Science (MS) degree in Genetics from the same institution from 1997 to 1999. Finally, Jeremy went on to earn a Doctor of Philosophy (PhD) degree in Biochemistry from the MRC Laboratory of Molecular Biology in Cambridge, UK, where they studied from 2001 to 2004.